A software-enhanced drug offering that combines prescription digital therapeutics with pharmacotherapy to add clinical benefit for specific medicines.

Click Therapeutics: A NY-based digital therapeutics provider developing healthcare software for unmet medical needs.
Click Therapeutics, founded in New York, is a digital therapeutics provider focused on developing healthcare software to address unmet medical needs. The company's core mission is to deliver safe and effective digital treatments to patients in need. Click Therapeutics offers a platform that enables the analysis and prescription of medical treatments through software applications, targeting conditions such as Major Depressive Disorder (MDD). Their market focus is on providing innovative, validated, and commercialized software as prescription medical treatments.
Notable affiliated people include key executives and experts in digital health and therapeutics. The company has garnered significant attention from investors and partners, including a collaboration with Otsuka Pharmaceutical. A key achievement is the FDA clearance of Rejoyn™, the first prescription digital therapeutic authorized for the adjunctive treatment of MDD symptoms. Click Therapeutics' impact lies in its pioneering approach to integrating software solutions into traditional healthcare, offering new avenues for treatment and improving patient outcomes.
Companies similar to Click Therapeutics include Remepy, Pear Therapeutics, ClickMedix and Better Therapeutics.
Click Therapeutics was founded in 2012.
Click Therapeutics' headquarters is located in New York City, NY, US.
Click Therapeutics' most recent funding round was for $20M (USD) in November 2023.
As of Nov 6, 2023, Click Therapeutics has raised a total of $946.4M (USD).
Click Therapeutics has 182 employees as of Feb 5, 2024.
ClickMedix
clickmedix.com